SEC Form 4 · accession 0001179110-17-002159
CATABASIS PHARMACEUTICALS INC · CATB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew John Nichols
Officer — Chief Scientific Officer
Period of report
Feb 9, 2017
Accepted (ET)
Feb 10, 2017 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454789
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.24 | Feb 9, 2017 | A | 100,000 | A | — | Feb 8, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This option was granted on February 9, 2017 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of February 9, 2017 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.